Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patients

2 Apr 2015

Abstract excerpt

Cetuximab, a monoclonal antibody against epidermal growth factor receptor (EGFR), was shown to be active in colorectal cancer. Although some patients who harbor K-ras wild-type tumors benefit from cetuximab treatment, 40 to 60% of patients with wild-type K-ras tumors do not respond to cetuximab. Currently, there is no universal marker or method of clinical utility that could guide the treatment of cetuximab in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Cancer Treatments and Studies
Share to Gastric Cancer Management and Outcomes
Share to Hepatocellular Carcinoma Treatment and Prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27081524
DOI: 10.1038/hgv.2015.9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patientsPMID 27081524Read ↗

Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer.Semantic proximity Read ↗

A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.Semantic proximity Read ↗

Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in PatientsSemantic proximity Read ↗

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.Semantic proximity Read ↗

Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature.Semantic proximity Read ↗

An integrated model for predicting KRAS dependencySemantic proximity Read ↗

Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab.Semantic proximity Read ↗

Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab.Semantic proximity Read ↗

A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation.Semantic proximity Read ↗

KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer.Semantic proximity Read ↗

Stem cell property epithelial‐to‐mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in <i>KRAS</i> wild‐type tumor cellsSemantic proximity Read ↗

Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.